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Serum mucosa-associated epithelial chemokine (MEC/CCL28) in atopic 
dermatitis: a specific marker for severity  
INTRODUCTION 
Atopic dermatitis (AD) is a common chronic 
inflammatory skin disorder of unknown etiology 
expressed early in life with peak incidence in early 
childhood. Disease development is primarily 
determined by as yet unknown genetic factors, 
leading to the accumulation of peripheral activated 
T lymphocytes in the skin. It was hypothesized that 
AD is associated with an unbalanced establishment 
of the peripheral T-lymphocyte system. Cutaneous 
lymphocyte-associated antigen (CLA)1 is a cell 
surface glycoprotein which has been postulated to 
play an important role in T-cell migration and 
homing to the skin. It has been proposed that inter-
action between T cells and epidermal keratinocytes 
plays a central role in the pathogenesis of AD2. 
Mucosa-associated epithelial chemokine (MEC 
or CCL28) is a CC chemokine that has been 
recently identified and characterized and is a 
functional ligand for CC chemokine receptor-3 and 
10 (CCR3 & 10). CCL28 gene is located on 
chromosome 5, and the corresponding cDNA 
encodes a 127 amino acid (AA) precursor protein 
with a putative 22 AA signal sequence. The signal 
sequence is cleaved to generate the 105 AA mature 
protein. Among human chemokines, CCL28 is most 
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similar to cutaneous T cell-attracting chemokine 
(CTACK or CCL27), sharing 40% AA identity.3  
CCL28 has been reported to chemoattract 
transfectants expressing the seven-transmembrane 
G-protein coupled CCR3 & CCR10. 
Desensitization experiments had confirmed CCR10 
specificity. CCR10, previously known as orphan G-
protein-coupled receptor (GPR-2), has been 
detected on the surface of T lymphocytes, dermal 
microvascular endothelial cells, and dermal 
fibroblasts, but mRNA expression studies suggest 
that it may be present on additional cell types. 
CCL28 induces calcium mobilization in human 
CCR10-expressing transfectants by CCL27, 
indicating that these chemokines share the new 
receptor, CCR10.4 
CCL28 is expressed in a variety of human cell 
types and tissues but it appears to be predominantly 
produced by epithelial cells. Its mRNA expression 
is most abundant in salivary and mammary glands, 
human saliva and breast milk.5 Significant mRNA 
expression has also been observed in other tissues 
associated with mucosal epithelial surfaces, 
including stomach, colon, rectum, nose and trachea. 
IL-10 -/- knock-out mice display increased CCL28 
expression in the stomach and Peyer’s patches, 
indicating that IL-10 may be CCL28 suppressive.6 
Studies showing CCL28 production in nasal and 
bronchial epithelial cell lines have suggested that it 
might also play a role in allergic respiratory 
diseases such as bronchial asthma (BA).  
To our knowledge, there are no clinical studies 
on serum CCL28 levels in allergic diseases in the 
pediatric age groups to date. Also, no data on 
CCL28 levels in other biological fluids of allergic 
children could be cited in literature. Therefore, this 
study was done to explore the expression of CCL28 
in AD and BA and hence its pathogenic role in such 
diseases and to identify the clinical relevance of 
measuring serum CCL28 in terms of disease 
activity and/or severity.  
   
METHODS 
This follow-up controlled study was conducted over 
a period of 9 months from the first of January to the 
end of September 2005. All patients were enrolled 
from the Pediatric Allergy and Immunology Unit 
and outpatient clinic of Ain Shams University 
Children’s Hospital, Cairo. An informed consent 
was obtained from the parents or caregivers of each 
child before enrollment. Children were divided into 
the following groups: 
Atopic Dermatitis (AD): This group comprised 36 
children with AD diagnosed by standardized 
diagnostic criteria7. Their ages ranged between 8 
and 120 months (mean ± SD = 47 ± 22 months). 
They comprised 20 boys (55.5%) and 16 (44.5%) 
girls. The parents were subjected to a questionnaire 
concerning the precipitating factor(s). A possible 
cause could be traced in 18 children being exposed 
to food allergens [egg (6), milk (5), banana (4), and 
fish (3)]. In 18 children, the cause was not clear. 
For convenience, the severity of AD was evaluated 
according to two scores. First, the Leicester Sign 
Score (LSS; range, 0 to 108), in which severity is 
scored by 6 clinical features (erythema, purulence, 
excoriation/crusting, dryness/scaling, cracking/ 
fissuring, and lichenification) graded at 6 defined 
body sites on a scale of 0 (none) to 3 (severe).8, 9 
Second, the Scoring Atopic Dermatitis (SCORAD) 
index system that was used to evaluate the severity 
of eczema. This index includes evaluation of extent, 
intensity, and subjective symptoms to a maximum 
score of 103 points.10 AD children were classified 
into 3 groups (mild, moderate, and severe) 
according to a proposal for severity grading of AD 
by using only objective criteria (mild AD, 
SCORAD score < 15; moderate AD, score = 15-40; 
and severe AD, score > 40).11 Sixteen children 
(44.5%) presented with severe AD, 11 (30.5%) with 
moderate severity, and 9 (25%) were categorized as 
having mild illness. In the 16 patients with severe 
AD, serum CCL28 levels were measured before 
and after treatment with topical corticosteroids in 
combination with oral anti-histamines. The 
response to treatment was scored by using the 
Physician's Global Assessment (PGA) score. The 
PGA is an overall assessment from 0 to 5 of a 
patient's eczema, taking into consideration the 
quality and extent of lesions relative to the baseline 
assessment (0 = clear [100%], 1 = almost clear 
[90% to 99% improvement], 2 = marked 
improvement [50% to 89%], 3 = modest 
improvement [<50%], 4 = no change, and 5 = 
worse). Twenty-two patients had AD only. The 
remaining 14 children had concomitant asthma 
(personal history and/or clinical evidences of 
respiratory allergy).  
Bronchial asthma (BA): This group comprised 23 
children enrolled while presenting with an acute 
asthmatic exacerbation. Their ages ranged between 
14 and 90 months (mean ± SD = 49 ± 16 months), 
and they comprised 12 boys (52%) and 11 (48%) 
girls. From history, the asthma exacerbations were 
triggered by exposure to allergens (food, animal 
allergens or both) in 12 children and upper 
respiratory tract infections in 5 children. In 6 
children, the triggering agent was not clear. Ten 
children (43.5%) presented with acute severe 
asthma, and the remaining 13 (56.5%) presented 
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with acute exacerbations of mild to  moderate 
severity based on clinical data and peak expiratory 
flowmetry (PEFR).12, 13 
Control group: This group comprised 21 healthy 
children without past, current or family history of 
allergic disorders. They were 12 (57%) males and 9 
(43%) females. Their ages ranged between 12 and 
120 months with a mean ± SD of 77 ± 26 months. 
They underwent clinical examination to exclude 
any concomitant illness particularly allergic 
disorders and parasitic infestations. Children with 
peripheral blood eosinophilia or elevated serum IgE 
for age were excluded.14 
 
Study measurements: 
Blood sampling: Four ml of venous blood were 
collected under complete aseptic conditions from 
each patient or control subject and were divided 
into 2 equal parts. One sample was mixed with 
EDTA as an anticoagulant for blood counting, and 
the other was left to clot for 30 minutes for serum 
CCL28 assay. After coagulation, the latter sample 
was centrifuged for 15 minutes at 1000 x g. The 
separated sera were divided into 3 aliquots and 
stored at -20°C for the subsequent assay of serum 
CCL28, lactate dehydrogenase (LDH), and total 
IgE. Repeated thawing and freezing was avoided. 
Hemolyzed samples were excluded. 
Serum CCL28/MEC assay: The kit used was a 
human CCL28 immunoassay (Quantikine R&D 
Systems, Inc. McKinley Place N.E., Minneapolis, 
Minnesota, MN 55413 U.S.A.). This assay employs 
the quantitative sandwich enzyme immunoassay 
technique using E coli-expressed recombinant 
human CCL28 and antibodies raised against the 
recombinant factor. Results obtained using natural 
human CCL28 showed linear curves that were 
parallel to the standard curves obtained using the 
Quantikine kit standards. 
A monoclonal antibody specific for CCL28 has 
been pre-coated onto a microplate. Standards and 
samples were pipetted into the wells and any 
CCL28 present was bound by the immobilized 
antibody. After washing away any unbound 
substances, a horseradish peroxidase-linked 
monoclonal antibody specific for CCL28 was added 
to the wells. Following a wash to remove any 
unbound antibody-enzyme reagent, a substrate 
solution of hydrogen peroxide-tetramethylbenzidine 
was added to the wells and color developed in 
proportion to the amount of CCL28 bound in the 
initial step. The color development was stopped by 
2N sulfuric acid and the intensity of the color was 
measured at 450 nm and 540 nm. Readings at 540 
nm were subtracted. For calculation of results, a 
standard curve was constructed on a log/log scale 
by plotting the mean absorbance for each standard 
on the y-axis against the concentration on the x-axis 
and drawing a best fit curve through the points on 
the graph. The minimum detectable dose (MDD) 
ranged from 0.58 - 6.05 pg/mL. The mean MDD 
was 2.58 pg/mL.  
Serum total IgE assay: This was performed in all 
subjects by quantitative enzyme immunoassay 
(Medix Biotech, San Carios, CA, USA). Results 
were expressed in IU/ml. Owing to the variability in 
serum total IgE levels with age in childhood, we 
calculated the percentage values from the reference 
ranges by dividing the subject’s actual level by the 
highest normal for age multiplied by 100.14 IgE 
levels used in the correlations were both the 
measured and the calculated percentage values. The 
serum total IgE level that exceeded the highest 
normal for age was considered elevated.   
Complete blood count:  Peripheral blood cells were 
counted by a  Coulter counter (Coulter MicroDiff 
18, Fullerton CA, USA). The differential leukocytic 
counts were estimated manually form the blood 
film and expressed in absolute count values. Infants 
and children whose absolute eosinophil counts 
(AEC) exceeded the normal reference values for 
age were considered to have peripheral blood 
eosinophilia. Blood sampling of all subjects was 
performed at the same time (10 am) daily to avoid 
diurnal variations in eosinophil counts.14 
Serum total lactate dehydrogenase (LDH) assay: 
Serum total LDH (U/L) was measured only in the 
AD group during flare and in the healthy subjects. 
LDH assay was performed on an automatic 
chemistry analyzer (Synchron CX5 system, 
Beckman, Inc., Fullerton, California U.S.A.). 
 
Statistical Analysis:  
All statistical analysis of the data was carried out 
using SPSS (Statistical Package for the Social 
Science) version 9.02 for Windows system. Data 
were expressed as mean, standard deviation (SD), 
median, and interquartile ranges IQR (25th and 75th 
percentiles). Student's "t" test was used for 
comparing parametric data. For non-parametric 
comparison of serum CCL28 among different 
groups, we used Mann-Whitney U test. The relation 
between the various numerical parameters was 
studied by the Pearson correlation coefficient (r) 
test with graphic representation using linear 
regression line; r value was considered weak if < 
0.5, moderate if ranged between 0.5-0.75 and strong 
if  > 0.75. p values below 0.05 for all tests were 
considered significant. 
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RESULTS 
Serum CCL28 levels of the studied groups (table 
1; figs 1 & 2): 
Serum CCL28 levels of AD patients during flare 
ranged between 687 and 2256 pg/ml (median = 
1530, mean ± SD = 1590.4 ± 724.3 pg/ml). These 
values were statistically comparable to the 
corresponding values of the same patients during 
quiescence, which ranged from 970 to 1980 pg/ml 
(median = 1477, mean ± SD = 1575.2 ± 522.1 
pg/ml) (Z = 1.1; p > 0.05). The healthy children had 
much lower serum CCL28 levels (range = 10 to 460 
pg/ml, median = 301, mean ± SD = 189.6 ± 92.8 
pg/ml) as compared to the patients’ data whether 
during flare (Z = 4.1; p < 0.0001) or quiescence (Z 
= 3.7; p < 0.0001) (Fig.1). 
Serum CCL28 levels of asthmatic patients 
during exacerbations ranged between 153 and 620 
pg/ml (median = 340, mean ± SD = 201.6 ± 109.5 
pg/ml). These values were statistically comparable 
to the values of controls (Z = 0.4; p > 0.05), but 
were significantly lower than the values of children 
with AD whether during flare (Z = 3.1; p < 0.0001) 
or quiescence (Z = 2.9; p < 0.0001) (Fig.2).  
Within the group of AD, 14 subjects had 
concomitant asthma as well. Their serum CCL28 
levels ranged from 832 to 2059 pg/ml (median = 
1425, mean ± SD = 1601 ± 428.3 pg/ml). These 
values were statistically comparable to the values of 
the AD only group whether during flare (Z = 0.7; p 
> 0.05) or quiescence (Z = 0.9; p > 0.05), but were 
significantly higher when compared to the values of 
subjects with BA only (Z = 2.9; p < 0.0001) (Fig.2) 
and the control group (Z = 3.9; p < 0.0001). 
Serum CCL28 levels in relation to other clinical 
and laboratory variables (figs 3-6): 
In our study, the mean SCORAD score values 
ranged between 10 and 65 (mean ± SD = 24.8 ± 
10.6). The median and mean ± SD of serum CCL28 
levels in the severe group (1809; 1754.8 ± 1110 
pg/mL) were significantly higher than the 
corresponding values of the mild group (759; 785.1 
± 153.3 pg/ml; Z = 2.5; p < 0.001) or the moderate 
group (1190; 1165.9 ± 586.5 pg/ml; Z = 1.8; p < 
0.01). Similarly, moderate cases had significantly 
higher values than mild ones (Fig. 3). Moreover, 
serum CCL28 levels correlated positively with the 
LSS and the SCORAD index (r = 0.89 and 0.70 
respectively, p < 0.001 for both) (Fig 4), indicating 
increased CCL28 expression with increased 
severity. 
A positive correlation could be elicited between 
the CCL28 serum levels during AD exacerbation 
and the corresponding values during remission 
meaning that the higher the level got during acute 
attacks the higher it remained after remission (r = 
0.91; p < 0.0001) (Fig.5). 
The mean (±SD) absolute eosinophil count 
values were statistically comparable among subjects 
with AD, BA, and AD associated with BA (650 ± 
235, 590 ± 197, and 660 ± 301 cells/mm3 
respectively). However, each value was 
significantly higher when compared to the control 
group (220 ± 90 cells / mm3; p < 0.01 for all 
groups). Serum CCL28 levels correlated positively 
with the absolute eosinophil count in all groups 
during flare (r = 0.73; 0.42 and 0.65 respectively, p 
< 0.01). Similar correlation was found in the AD 
group during quiescence (r = 0.87; p < 0.01). 
Another positive correlation could be elicited 
between the SCORAD index and the absolute 
eosinophil count in the AD group (r = 0.46, p < 
0.05).  
The studied patient groups (AD, BA, and AD 
associated with BA) were statistically comparable 
in terms of serum IgE levels (500.6 ± 385.6, 655 ± 
492.5, and 627.9 ± 336.6 IU/ml respectively) and 
each mean value was significantly higher than that 
of the healthy control subjects (140.6 ± 19.7 IU/ml; 
p < 0.001). Serum CCL28 or SCORAD index 
values could not be related by correlation 
coefficient to IgE concentrations or IgE percent 
values from normal in the studied groups.  
Serum total LDH levels of AD patients during 
flare ranged between 130 and 1450 U/L (mean ± 
SD = 1036.6 ± 486.2 U/L). These values were 
significantly higher than the control values (range = 
40-110 U/L; mean ± SD = 70 ± 25 U/L, t = 1.2; p < 
0.05). LDH values correlated positively with each 
of the serum CCL28 levels and the SCORAD 
indices (Fig.6).  
Serum CCL28 levels could not be correlated to 
age, weight centiles, and height centiles of subjects 
in each patient group. CCL28 expression was not 
influenced by age, gender, or family history. In the 
asthma group, CCL28 levels did not vary according 
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Table 1. Serum mucosa-associated epithelial chemokine (MEC/CCL28) in 




Atopic Dermatitis (AD) BA 
(Flare) 
AD + BA 
(Flare) 
Control 
group Flare Quiescence 
Range 687-2256 970-1980 153-620 832-2059 10-460 
Median 1530 1477 340 1425 301 
IQR 1032 640 240 785 220 
Mean 1590.4 1575.2 201.6 1601 189.6 
SD 724.3 522.1 109.5 428.3 92.8 
Z1 1.1    
Z2 3.1 * 2.9 *    
Z3 0.7 0.9    
Z4   2.9 *   
Z5 4.1 * 3.7 * 0.4 3.9 *  
AD: Atopic dermatitis; BA: Bronchial asthma; IQR: Interquartile range; MEC: Mucosa-
associated epithelial chemokine; SD: Standard deviation 
Mann-Whitney test results: Z1 = AD flare versus quiescence; Z2 = AD versus BA; Z3 = 
AD versus (both AD & BA); Z4 = BA versus (both AD & BA); Z5 = patients versus 
controls 
































Z = 1.1 
P > 0.05
Z = 3.7
 P < 0.0001
Z = 4.1; P < 0.0001
Atopic Dermatitis  
Figure 1. Box-plot summary of serum mucosa-associated 
epithelial chemokine (MEC/CCL28) levels (pg/ml) in atopic 
dermatitis (AD) and control subjects. Mann–Whitney test 
was used in the comparisons. Black squares represent the 
median and the boxes encompass the interquartiles (25th and 






































Z = 3.1 
P < 0.0001
Z =2.9
 P < 0.0001
Z = 0.7; P > 0.05
 
Figure 2. Box-plot summary of serum mucosa-associated 
epithelial chemokine (MEC/CCL28) levels (pg/ml) in the studied 



































 P < 0.01
Z = 2.5; P < 0.001
 
Figure 3. Box-plot summary of serum mucosa-associated 
epithelial chemokine (MEC/CCL28) levels (pg/ml) variation 
according to atopic dermatitis SCORAD index of severity. Mann–
Whitney test was used in the comparisons. 
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Figure 4. Serum mucosa-associated epithelial chemokine (MEC/CCL28) levels (pg/ml) in 
relation to atopic dermatitis severity scores; the LSS (Fig. 4A), and the SCORAD index (Fig. 
4B). 
 
























Figure 5. Positive correlation between the atopic dermatitis flare 
and remission levels of serum CCL28 (pg/ml). 
 





































































Figure 6. Positive correlations between serum total lactate dehydrogenase (LDH) (U/L) and 





MEC or CCL28 has been implicated in the homing 
of lymphocytes to the inflammatory sites. It was 
assumed to play an important role in T-cell 
migration to skin in adult AD, psoriasis vulgaris 
and bullous pemphigoid15; however, the expression 
of CCL28 in both normal children and children 
with atopic diseases has not been extensively 
studied. To evaluate a possible role for CCL28 
estimation in pediatric allergy, we measured serum 
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CCL28 levels in phenotypically well-defined 
groups of allergic children (AD, BA, and AD 
associated with BA) in comparison to a group of 
healthy non-atopic age and sex-matched control 
subjects. 
We observed that serum CCL28 levels were 
specifically elevated in patients with AD 
irrespective of allergic respiratory comorbidity. The 
study revealed that the levels in AD whether during 
flare or exacerbation were significantly higher than 
the control (Fig.1) and asthmatic groups (Fig.2). 
Our results which conform with those of Kagami et 
al.15 probably reflect the upregulation of CCL28 in 
AD, presenting a potentially useful marker for the 
presence of an atopic reaction. CCL28 regulation 
by allergen exposure and microbial products 
suggests an important role for CCL28 in the 
initiation and amplification of the atopic skin 
response. The failure to demonstrate significant 
reduction in serum CCL28 levels after remission of 
the flare could be due to an ongoing process of 
subclinical allergic cutaneous inflammation. Also, it 
could be indicative of the need for more intensive 
non-conventional anti-inflammatory therapy. 
Therefore, we suggest that serum CCL28 levels be 
used as a marker of the ongoing inflammatory 
activity in the skin. 
Among human chemokines, CTACK (or 
CCL27) is most similar to MEC (or CCL28), 
sharing 40% AA identity3. Like CCL28, CCL27 is 
also known to recruit CLA+ memory Th2 
lymphocytes.16 Dose-dependent chemotaxis of 
identical lymphocyte populations in response to 
CCL28 is nearly indistinguishable from that 
exhibited by CCL27; except that CCL28 has higher 
maximal activity.17, 18 CCL27 was found to be 
expressed at high levels in the epidermis of lesional 
skin biopsy specimens from patients with AD 
compared with non-lesional skin.19, 20 Owing to the 
tissue-specific expression profile and receptor 
specificity of both chemokines (CCL27 & CCL28), 
a definite role of CCL28 in AD is highly suggested. 
CCL28 is expressed in a variety of human 
tissues, and it appears to be predominantly 
produced by epithelial cells.5 It is strongly 
expressed constitutively in lesional epidermal 
keratinocytes of patients with AD and psoriasis 
vulgaris.15 In vitro, CCL28 displays chemotactic 
activity for resting CD4+ CD8+ T cells.4 These cells 
can be detected in a significant proportion in 
peripheral blood of AD children.1 This may suggest 
a faulty maturation of the T-lymphocyte system as a 
basic pathophysiological change in AD, leading to 
skin inflammation with CD4+ CD8+ T lymphocytes 
resembling immature T cells.21 This is likely to lead 
to skewing of many immune reactions in those 
patients.  
CCL28 is also displayed by cutaneous venules, 
and is strongly expressed on endothelial cells. It is 
thought to trigger vascular arrest of circulating skin 
homing memory T cells, which uniformly express 
the CCR10 particularly CLA+CCR10+ memory T 
cells. Chronic cutaneous inflammation induces 
CD4+ T cells expressing E-selectin binding activity 
in draining lymph node. CLA is a ligand for E-
selectin, an adhesion molecule, which is critical in 
recruiting T cells. These E-selectin ligand+ T cells 
migrate efficiently to CCL28 and to CCL27 as 
well.22, 23 This could reinforce the hypothesis that 
CCL28 and CCL27 may work in a sequential way, 
with CCL28 acting mainly in the first steps of T-
cell recruitment by inducing integrin-dependent 
adhesion and transendothelial migration of T cells 
and CCL27 playing a major role in the migration of 
T cells into the upper layers of the skin. Finally, T 
cells infiltrating the epidermis may result in the 
induction of apoptosis in keratinocytes, resulting in 
spongiosis, the histologic hallmark of eczema. 
To test the specificity of CCL28 response in AD, 
we sought to investigate its expression in a group of 
asthmatic subjects during acute exacerbations. The 
serum CCL28 levels of the asthmatic patients were 
statistically comparable to the values of controls, 
but were significantly lower as compared to the 
values of children with AD whether during flare or 
quiescence. The normal values of serum CCL28 in 
our asthmatic patients indicates that the results of 
studies that use bronchial cell lines and mouse 
models24, 25 cannot simply be extrapolated to human 
studies in vivo. It is also possible that the local 
production of CCL28 in mucosal epithelial cells 
may be insufficient to lead to a systemic increase. 
In children who presented with concomitant 
cutaneous and respiratory allergy (BA & AD), the 
over expression of CCL28 can be ascribed to the 
presence of AD, providing further evidence for the 
implication of CCL28 in atopic cutaneous 
responses. Our data may thus reflect the 
upregulation of CCL28 in AD specifically; 
however, our findings are still limited by the sample 
size. 
Serum CCL28 levels in subjects categorized as 
severe AD cases were significantly higher as 
compared to the moderate and mild groups with a 
positive correlation to the LSS and the SCORAD 
severity scores (Fig.3&4). This substantiates the 
usefulness of this parameter as a skin-specific 
objective marker of disease severity in AD. 
A large variety of laboratory measurements26, 27 
have been linked to disease activity and severity in 
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AD, however most of them lack specificity. The 
high levels of IgE in AD have not been 
satisfactorily explained but can be ascribed to a 
deficiency of IgE isotype-specific "suppressor" T-
cell function. It is not established that AD is 
exclusively an IgE-mediated allergic disorder; and 
it is difficult to demonstrate consistently a role for 
allergens in the pathogenesis. Although patients 
with AD frequently possess IgE antibody specific 
for inhalants or food allergens, it is not generally 
possible to induce skin lesions or AD by intrader-
mal injection of the suspected allergen.28, 29 
Moreover, typical lesions of AD may occur in 
individuals with X-linked agammaglobulinemia, 
who have virtually no IgE. 7 
Serum CCL28 levels and the SCORAD score 
results in the current study could not be correlated 
to the serum total IgE concentrations or % values 
from normal during AD flare. This was not 
concordant with some reports27, 28. The discrepancy 
can be ascribed to the small number of cases with 
elevated IgE (6 children only). We also recruited 
subjects at different stages of disease activity and 
serum total IgE levels might fluctuate throughout 
the disease stages.  
On the other hand, serum CCL28 concentrations 
and the SCORAD indices correlated positively with 
the absolute eosinophil counts both during AD flare 
and quiescence. Previous studies had identified 
eosinophil chemoattractant properties of CCL28 
using human cells.4, 24. It is not clear whether 
CCL28 may have a role in regulating the 
constitutive numbers of eosinophils in peripheral 
blood by inducing eosinophil chemotaxis in a 
CCR3 and CCR10-dependent manner. Animal 
studies confirmed that CCL28 was a 
chemoattractant for murine eosinophils. There 
appears to be a temporal relationship of CCL28 
production with eotaxin and other CCR3 ligands in 
animal models.24 Perhaps they play an important 
role for the localization of eosinophils around the 
inflammatory sites. Interestingly, anti-CCL28-
treated animals showed also reduced eosinophil 
accumulation.30 Therefore, CCL28, a CCR3 ligand, 
may be important for various stages of eosinophil 
migration and/or activation within tissues. It might 
be possible one day to target tissue eosinophilia in 
severe allergic diseases by manipulating 
CCL28/CCR3 interactions. 
Serum total LDH levels of our AD patients 
during flare were significantly higher as compared 
to controls. Moreover, significant positive 
correlations could be elicited between serum LDH 
levels during flare and serum CCL28 
concentrations and SCORAD indices (Fig.6). 
Elevated levels can be attributed to its release from 
damaged lesional epidermal cells into peripheral 
blood reflecting the extent of skin involvement and 
the degree of epidermal injury. LDH was 
previously reported as a useful yet non specific 
marker for severity of skin eruption being elevated 
in many other diseases.31, 32 
In conclusion, it seems that serum CCL28 
expression is up regulated in children with AD 
irrespective of allergic respiratory comorbidity. It 
might be one of the important chemokines in the 
lesional formation of AD and might have a distinct 
role in the development of atopy/allergy skin 
phenotypes. It could be a useful specific 
inflammatory marker for assessing AD severity in 
children. Further research using immuno-
histochemical staining of CCL28 in the lesional AD 
skin and other cutaneous hypersensitivities are 
warranted as well as studies addressing the relations 
between its expression and the conventional lines of 
treatment used. A potential role of CCL28 in 
respiratory allergy deserves further evaluation on a 
wider scale. Moreover, the effect of CCL28 
antagonists and other immunotherapeutics, like 
monoclonal antibodies on the CCL28 kinetics is 
worth evaluation. CCL28 antagonism may provide 
a conceptual basis for the development of new 
therapeutic strategies in severe AD. 
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